The biologics anakinra and etanercept prevent cytokine-induced growth retardation in cultured fetal rat metatarsal bones

Hormone Research in Paediatrics

Volumn 76, Issue 4, 2011, Pages 278-285

  Fernandez Vojvodich, Paola ^a   Karimian, Elham ^a   Sävendahl, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anakinra; Etanercept; Impaired bone growth; Reduced adult height

Indexed keywords

CYTOKINE; ETANERCEPT; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE GROWTH; GROWTH RETARDATION; METATARSAL BONE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BONE DEVELOPMENT; CYTOKINES; IMMUNOGLOBULIN G; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; METATARSAL BONES; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054903998     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000330726     Document Type: Article

References (33)

1. Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P: Growth in paediatric Crohn's disease. Horm Res 2002; 58(suppl 1):11-15. (Pubitemid 35316830)
2. Simon D, Fernando C, Czernichow P, Prieur AM: Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002; 29: 1296-1300. (Pubitemid 34601968)
3. Polito C, Strano CG, Olivieri AN, Alessio M, Iammarrone CS, Todisco N, Papale MR: Growth retardation in non-steroid treated juvenile rheumatoid arthritis. Scand J Rheumatol 1997; 26: 99-103. (Pubitemid 27168740)
4. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ: Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46: 694-700. (Pubitemid 30305788)
5. Funakoshi K, Sugimura K, Anezaki K, Bannai H, Ishizuka K, Asakura H: Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 1998; 59: 73-78. (Pubitemid 28022450)
6. Kutukculer N, Caglayan S, Aydogdu F: Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998; 17: 288-292. (Pubitemid 28417039)
7. Yilmaz M, Kendirli SG, Altintas D, Bingol G, Antmen B: Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001; 20: 30-35. (Pubitemid 32208444)
8. Macrae VE, Wong SC, Smith W, Gracie A, McInnes I, Galea P, Gardner-Medwin J, Farquharson C, Ahmed SF: Cytokine profiling and in vitro studies of murine bone growth using biological fluids from children with juvenile idiopathic arthritis. Clin Endocrinol (Oxf) 2007; 67: 442-448. (Pubitemid 47283845)
9. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E: Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-650. (Pubitemid 27097665)
10. Mainardi GL, Saleri R, Tamanini C, Baratta M: Effects of interleukin-1-beta, interleukin-6 and tumor necrosis factor-alpha, alone or in association with hexarelin or galanin, on growth hormone gene expression and growth hormone release from pig pituitary cells. Horm Res 2002; 58: 180-186.
11. Martensson K, Chrysis D, Sävendahl L: Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004; 19: 1805-1812. (Pubitemid 41103431)
12. MacRae VE, Farquharson C, Ahmed SF: The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines. J Endocrinol 2006; 189: 319-328.
13. Bechtold S, Ripperger P, Dalla Pozza R, Bonfig W, Hafner R, Michels H, Schwarz HP: Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 2007; 92: 3013-3018. (Pubitemid 47236364)
14. Chrysis D, Ritzen EM, Sävendahl L: Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 2003; 176: 331-337. (Pubitemid 36410417)
15. Amgen: Kineret® (Anakinra) Product Monograph, 2006.
16. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-1486. (Pubitemid 40664091)
17. Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loet X, Sibilia J: Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-308.
18. Ilowite N, Porras O, Reiff A, Rudge S, Punaro M, Martin A, Allen R, Harville T, Sun YN, Bevirt T, Aras G, Appleton B: Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-137.
19. Wyeth: Enbrel® (Etanercept) US Prescribing Information, 2008.
20. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH: Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-1504.
21. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H: Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005; 45: 246-256.
22. Schmeling H, Seliger E, Horneff G: Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol 2003; 21: 779-784.
23. Tynjala P, Lahdenne P, Vahasalo P, Kautiainen H, Honkanen V: Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006; 65: 1044-1049.
24. Vojvodich PF, Hansen JB, Andersson U, Sävendahl L, Hagelberg S: Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007; 34: 2481-2485.
25. R&D Systems I: Anti-Rat IL-1β Antibody, 2010.
26. R&D Systems I: Anti-Rat TNF-α /TNFSF1A Antibody, 2009.
27. Chagin AS, Karimian E, Zaman F, Takigawa M, Chrysis D, Sävendahl L: Tamoxifen induces permanent growth arrest through selective induction of apoptosis in growth plate chondrocytes in cultured rat metatarsal bones. Bone 2007; 40: 1415-1424.
28. Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A: Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 2001; 28: 1677-1680.
29. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME: Comparison of 2 doses of etanercept (50 vs. 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006; 33: 659-664.
30. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, Furst DE: Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58: 1921-1930.
31. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T: The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10:R67.
32. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50: 1412-1419.
33. Fintini D, Brufani C, Cappa M: Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther Clin Risk Manag 2009; 5: 553-559.